- Home
- WKEY vs ATOS Comparison
WKEY vs ATOS Comparison
Compare WKEY & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKEY
- ATOS
- Stock Information
- Founded
- WKEY 1999
- ATOS 2009
- Country
- WKEY Switzerland
- ATOS United States
- Employees
- WKEY N/A
- ATOS N/A
- Industry
- WKEY EDP Services
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- WKEY Technology
- ATOS Health Care
- Exchange
- WKEY Nasdaq
- ATOS Nasdaq
- Market Cap
- WKEY N/A
- ATOS 96.8M
- IPO Year
- WKEY N/A
- ATOS 2012
- Fundamental
- Price
- WKEY $4.63
- ATOS $0.81
- Analyst Decision
- WKEY Strong Buy
- ATOS Strong Buy
- Analyst Count
- WKEY 1
- ATOS 3
- Target Price
- WKEY $4.00
- ATOS $7.13
- AVG Volume (30 Days)
- WKEY 89.0K
- ATOS 620.7K
- Earning Date
- WKEY 05-19-2025
- ATOS 05-16-2025
- Dividend Yield
- WKEY N/A
- ATOS N/A
- EPS Growth
- WKEY N/A
- ATOS N/A
- EPS
- WKEY N/A
- ATOS N/A
- Revenue
- WKEY $11,875,000.00
- ATOS N/A
- Revenue This Year
- WKEY $18.18
- ATOS N/A
- Revenue Next Year
- WKEY $112.51
- ATOS N/A
- P/E Ratio
- WKEY N/A
- ATOS N/A
- Revenue Growth
- WKEY N/A
- ATOS N/A
- 52 Week Low
- WKEY $1.61
- ATOS $0.55
- 52 Week High
- WKEY $14.00
- ATOS $1.81
- Technical
- Relative Strength Index (RSI)
- WKEY 59.62
- ATOS 56.67
- Support Level
- WKEY $4.10
- ATOS $0.59
- Resistance Level
- WKEY $4.53
- ATOS $0.92
- Average True Range (ATR)
- WKEY 0.33
- ATOS 0.07
- MACD
- WKEY 0.12
- ATOS 0.01
- Stochastic Oscillator
- WKEY 86.16
- ATOS 62.44
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.